FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE
ASCENDING DOSES OF INTRATHECALLY ADMINISTERED ALN-SNCA
IN PARTICIPANTS WITH EARLY PARKINSON¿S DISEASE
- Registry ID
- ALN-SNCA-PD-2482
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- REGENERON PHARMACEUTICALS INC
- Start date
- 2025-12-05
- Last update
- 2025-09-11
Conditions
Related clinical trials
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF
INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY STAGE PARKINSON’S DISEASE
- PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF MIDBRAIN DOPAMINERGIC NEURONAL CELL THERAPY (BEMDANEPROCEL) FOR PARTICIPANTS WITH PARKINSON'S DISEASE
- TALLMAN FAMILY ENERGIZES RESEARCH TO HELP ALLEVIATE NEUROINFLAMMATION IN PARKINSONS DISEASE-"TALLER THAN PD". A PHASE 2 FUTILLITY STUDY TO EVALUATE THE EFFICACY,SAFETY AND TOLERABILITY OF HYDROXYCHLOROQUINE IN SUBJECT WITH EARLY TREATED PARKINSON'S DISEASE
- A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON¿S DISEASE.
- PHASE 1 STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF HUMAN EMBRYONIC STEM CELL-DERIVED MIDBRAIN DOPAMINE NEURON CELL THERAPY (MSK-DA01) FOR ADVANCED PARKINSON¿S DISEASE (STEM-PARKINSONS)
- A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY PARKINSON'S DISEASE
View on source registry